Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (11186)	11/15/1997 5:26:00 PM
From: Andrew H	Read Replies (2) \| Respond to of 32384

Sounds like quite a story. One thing I find interesting is that while your comments on other threads are always quite informed, the negative posters who visit here know next to nothing about biotechnology or LGND. Nor do they have any interest in learning. AMLN still has a good chance to get approval for Pramlintide, although the timeline has been pushed out quite a bit. They are very likely to receive approval for Type 1, although Type 11 looks pretty questionable at this point. AGPH is a great company and probably has the best protease inhibitor on the market. Many of us were hoping that the cocktail approach would defeat the virus, but it appears that will not happen at this time. However, I think the AGPH drug will hold up better than some against resistant varieties.